Skip to Content

Join the 'Acromegaly' group to help and get support from people like you.

Acromegaly News

U.S. Oncologists Decry High Cost of Cancer Drugs

Posted 23 Jul 2015 by Drugs.com

THURSDAY, July 23, 2015 – Soaring costs for cancer drugs are hurting patient care in the United States, a group of top oncologists claim. "High cancer-drug prices are affecting the care of patients with cancer and our health care system," Dr. Ayalew Tefferi, a hematologist at Mayo Clinic in Rochester, Minn., said in a Mayo news release. Tefferi and his colleagues made a number of recommendations on how to address the problem in a commentary published July 23 in the Mayo Clinic Proceedings. Allowing Medicare to negotiate drug prices is one of the suggestions the team of 118 leading cancer experts offered as a possible solution. Along with their recommendations, the group also expressed support for a patient-based grassroots movement on change.org that is demanding action on the issue. "The average gross household income in the U.S. is about $52,000 per year. For an insured patient with ... Read more

Related support groups: Cancer, Provera, Depo-Provera, Methotrexate, Breast Cancer, Accutane, Lupron, Prostate Cancer, Tamoxifen, Medroxyprogesterone, Arimidex, Tretinoin, Fluorouracil, Lupron Depot, Femara, Lung Cancer, Gleevec, Renal Cell Carcinoma, Colorectal Cancer, Isotretinoin

Novartis Gains FDA Approval for Signifor LAR to Treat Patients with Acromegaly

Posted 16 Dec 2014 by Drugs.com

EAST HANOVER, N.J., Dec. 16, 2014 Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor long-acting release (LAR)* (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. The approval of Signifor LAR, a next-generation somatostatin analog (SSA), helps address a critical unmet need among the acromegaly patient population. Signifor LAR has been studied and found effective in both medically naive patients with acromegaly who have had prior surgery or for whom surgery was not an option, as well as patients whose disease is not fully controlled on first generation SSAs2. Acromegaly is a rare, debilitating endocrine disorder caused by the excess production of growth hormone (GH) and insulin-like growth factor-1 ... Read more

Related support groups: Acromegaly, Signifor, Pasireotide

Scientists May Have Spotted Genetic Cause of 'Gigantism'

Posted 3 Dec 2014 by Drugs.com

WEDNESDAY, Dec. 3, 2014 – Researchers say they've honed in on the possible genetic cause of a rare condition called gigantism that causes excessive growth in children. "Gigantism is a disease in childhood that characterized by excessive growth, resulting from an excess of growth hormone production" by the pituitary gland, explained Dr. Patricia Vuguin, a pediatric endocrinologist at Cohen Children's Medical Center in New Hyde Park, NY. "In adult patients, the same condition is called acromegaly," said Vuguin, who was not involved in the new study. According to researchers at the U.S. National Institute of Child Health and Human Development (NICHD), some people with gigantism have a tumor in the pituitary gland that secretes extra hormone, while others have an oversized pituitary. People with gigantism typically grow rapidly, are abnormally tall with large hands and feet, and may have ... Read more

Related support groups: Acromegaly

Fewer Cancer Patients May Be Depressed Than Thought

Posted 20 Jan 2011 by Drugs.com

THURSDAY, Jan. 20 – The rate of depression among cancer patients may be lower than previously believed, a new study indicates. An international team of researchers analyzed 94 studies involving more than 14,000 patients and found that about one-sixth of cancer patients suffer depression and about one-third have a more widely defined mood disorder. Only modest rates of depression and anxiety occurred in cancer patients in the first five years after diagnosis, which suggests that depression is not inevitable in these patients, the researchers said. Only when it was combined with other mood disorders was depression common, occurring in 30 percent of hospitalized cancer patients. The study is published online Jan. 19 in The Lancet Oncology. Rates of depression and anxiety were not significantly different between patients receiving palliative care (care designed to ease pain and increase ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Basal Cell Carcinoma, Non-Small Cell Lung Cancer, Breast Cancer, Metastatic, Brain Tumor, Melanoma, Skin Cancer, Pancreatic Cancer, Osteosarcoma, Ovarian Cancer, Endometrial Cancer, Small Cell Lung Cancer, Breast Cancer - Adjuvant, Cervical Cancer, Bladder Cancer

Pain Relief Often Delayed for Cancer Patients

Posted 16 Mar 2010 by Drugs.com

TUESDAY, March 16 – Palliative care services, which help people who are seriously ill relieve symptoms such as pain, are now found at most U.S. cancer centers, but many programs don't interact with patients until it's too late, study findings show. Dr. David Hui, of the University of Texas M.D. Anderson Cancer Center in Houston, and his colleagues surveyed 71 U.S. National Cancer Institute-designated cancer centers and randomly surveyed 71 other cancer centers. They received responses from 71 percent of 142 executives and 82 percent of 120 program leaders. The researchers also found that the NCI cancer centers were more likely to have palliative care programs and physicians. A report on the survey was published in the March 17 issue of the Journal of the American Medical Association. "Palliative care outpatient clinics, inpatient consultation teams, palliative care units and hospices ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Basal Cell Carcinoma, Breast Cancer, Metastatic, Non-Small Cell Lung Cancer, Brain Tumor, Melanoma, Skin Cancer, Pancreatic Cancer, Osteosarcoma, Ovarian Cancer, Endometrial Cancer, Small Cell Lung Cancer, Breast Cancer - Adjuvant, Cervical Cancer, Bladder Cancer

U.S. Cancer Cases, Deaths Continue to Drop

Posted 8 Dec 2009 by Drugs.com

MONDAY, Dec. 7 – Better screening, healthier living and new treatments have all continued to help cut the annual number of cancer cases and deaths in the United States, a new report says. The findings showed that new cancer cases and deaths from cancer have declined significantly for both men and women and for most racial/ethnic populations. These decreases were largely due to decreased incidence and death from lung, prostate and colon cancer among men and a drop in two of the three leading cancers in women (breast and colon cancers). New diagnoses for all types of cancer in the United States declined almost 1 percent per year from 1999 to 2006 and cancer deaths dropped 1.6 percent per year from 2001 to 2006. The report, which appears in the Dec. 7 online edition of Cancer, was compiled from data by the American Cancer Society, the U.S. Centers for Disease Control and Prevention, the ... Read more

Related support groups: Cancer, Breast Cancer, Prostate Cancer, Lung Cancer, Renal Cell Carcinoma, Colorectal Cancer, Basal Cell Carcinoma, Breast Cancer, Metastatic, Non-Small Cell Lung Cancer, Brain Tumor, Melanoma, Skin Cancer, Pancreatic Cancer, Osteosarcoma, Ovarian Cancer, Endometrial Cancer, Small Cell Lung Cancer, Breast Cancer - Adjuvant, Cervical Cancer, Bladder Cancer

Ask a Question

Further Information

Related Condition Support Groups

Pituitary Tumor

Related Drug Support Groups

bromocriptine, Parlodel, octreotide, Sandostatin, lanreotide, Somavert, Somatuline Depot, Sandostatin LAR Depot, pasireotide, Signifor LAR, pegvisomant